Bharat Serums and Vaccines would run as an independent business, says Mankind’s Rajeev Juneja

TTK’s human pharma business to be absorbed into Mankind’s consumer healthcare business
Days after Mankind Pharma inked a ₹13,630 crore deal to buy Bharat Serums and Vaccines (BSV), its top management said BSV would run as an independent business, reporting to the Mankind board.
BSV presented itself as an attractive opportunity, not just as a business entity, but also because it had a capable management team that had turned it around to what it is today, Rajeev Juneja, Mankind Pharma Vice-Chairman and Managing Director, told. In fact, Mankind had looked at BSV five years ago as well, but it is a very different company today, he said, of the company it revisited late last year.
Giving broad contours of the integration process, Juneja said, TTK Healthcare’s human pharma business – acquired by then Advent-backed BSV about two years ago – would be absorbed into Mankind’s consumer healthcare business. Mankind expects the BVS acquisition to bring in synergistic benefits of ₹50-100 crore in 12 -24 months, he added.
Source: Thehindubusinessline